Whilst accounting for a small proportion of cancer cases—0.1% of BC and around 1% of PCa—the risk for carriers to develop BC increases up to 1% and 7–8%, while for PCa it ranges to almost 4-fold increase and from 3 to 8.6-fold increase, for BRCA1 and BRCA2 mutations, respectively [130,131,132]. This evidence concerns the gene BRCA1 and posterior cortical atrophy.